PTGER1 (Prostaglandin E Receptor 1) antibodies are essential tools for studying the EP1 receptor, a G protein-coupled receptor (GPCR) activated by prostaglandin E2 (PGE2). PTGER1. encoded by the *PTGER1* gene, mediates various physiological and pathological processes, including inflammation, pain signaling, and cellular proliferation. It couples primarily to Gq proteins, triggering intracellular calcium mobilization and protein kinase C activation, distinguishing it from other EP receptor subtypes (EP2. EP3. EP4) linked to cAMP pathways.
Research using PTGER1 antibodies focuses on elucidating its role in diseases such as cancer, inflammatory disorders, and neurological conditions. In cancer, PTGER1 overexpression correlates with tumor growth and metastasis, making it a potential therapeutic target. Antibodies against PTGER1 enable detection of receptor expression in tissues via techniques like immunohistochemistry, Western blotting, or flow cytometry, aiding in biomarker studies. They also assist in functional assays to explore ligand-receptor interactions or downstream signaling modulation.
Commercial PTGER1 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes (e.g., extracellular loops or intracellular domains). Validation includes knockout controls and tissue-specific staining patterns. Challenges include ensuring specificity due to structural homology among GPCRs. Recent studies also investigate PTGER1's crosstalk with other signaling pathways, highlighting its complex role in homeostasis and disease, thus underscoring the antibody's utility in mechanistic and translational research.